Microvascular benefits of hypertension and glucose control in type 2 diabetes.
van Rensburg
B W
BW
D000419:Albuminuria / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008833:Microcirculation / Q000187:drug effects*; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human
N Engl J Med. 2008 Jun 12;358(24):2633-5
18539919
N Engl J Med. 2008 Jun 12;358(24):2545-59
18539917
N Engl J Med. 1998 Jul 9;339(2):69-75
9654536
N Engl J Med. 2008 Apr 10;358(15):1547-59
18378520
N Engl J Med. 2008 Feb 7;358(6):580-91
18256393
N Engl J Med. 2008 Jun 12;358(24):2560-72
18539916